AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

AstraZeneca (AZN) has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.The CAPItello-281 study evaluated the combination of Truqap, J&J’s (JNJ) Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).Results from the study showed that patients treated with this combin ...